The CeQur management team has members with proven records of success in the fields of diabetes and medical device development. Together, the team has the competencies, experience and passion to successfully commercialize safe and effective advances in drug delivery technology.

Eric Milledge

Chairman & Chairman of the Board of CeQur. Milledge is a 34-year veteran of Johnson and Johnson Corporation, where he retired as Group Chairman of Lifescan. During his tenure, Milledge led the acquisition of Animas Corporation, which enabled J&J to become a major force in the insulin pump arena. Milledge had also served as president of Ortho Pharmaceuticals and as a board member of the Johnson and Johnson Development Corporation, the company's internal venture arm.

James Peterson

Chief Executive Officer and Vice-Chairman of CeQur. A medical technology industry veteran, Peterson was formerly President and CEO of Haemonetics (NYSE:HAE). He serves on the board of the Joslin Diabetes Center and as Counselor to the Diabetes Technology Society. He is a former advisor to Warburg Pincus on diabetes investments, as well as former Chairman of M2 Medical, a maker of disposable insulin pumps for type 1 diabetes patients.

Mike Hassman

President and Chief Operating Officer at CeQur, has over 15 years of medical device manufacturing management experience. As former Senior Vice President of Operations and Manufacturing at Accellent and Director of Manufacturing at Smith & Nephew and Stryker, Hassman led the manufacturing efforts for an orthopedic start-up.

Douglas Gunthardt

Executive Vice President and Chief Financial Officer of CeQur. Douglas has 20 years international leadership experience with both American high-tech and Swiss life science corporations in business development, finance and general management. He was former CEO CFO of Siegfried (SWX:SFZN) and Int'l Director F & A of Haemonetics. He currently serves as a board member of Ricola AG.

Mads Dall

Executive Vice President of Strategy and Business Development. In his 11-year management career in the Novo Nordisk international diabetes business he served as as Vice President in the area of insulin delivery and glucose monitoring systems, and also worked in business development, sales and operations and project management capacities at the company.

Robert O'Holla

Executive Vice President of Regulatory Affairs, CeQur. O'Holla began his regulatory career in 1975, after several years in medical device and drug development. He spent 33 years at Johnson & Johnson, where he most recently served as worldwide vice president of regulatory affairs in the medical devices and diagnostics group. O'Holla is a longtime leader in AdvaMed, the premier medical technology industry group, and has been recognized by both this organization and the Regulatory Affairs Professionals Society as an outstanding professional and contributor in his field.

Peter Gravesen

Chief Technology Officer. With 20 years of R&D experience in microfluidics and eight years specifically in medical device dosing development, Gravesen served as former head of microfluidics R&D at Danfoss and as a medical device engineer. He earned his PhD in microfluidics and completed his post-doctorate studies at MIT.

Jay Warner

Senior Vice President Clinical and Commercialization at CeQur. Warner's career in diabetes marketing and sales spanned 16 years at Eli Lilly and Company, where he served as Leader for the U.S. Byetta brand team and led the U.S. and Global Diabetes Market Research. While at Lilly, Warner was instrumental in the successful launch of more than seven new diabetes products.